Key Points
- HCA SVP Christopher Wyatt sold 4,000 shares for $2.02M on Feb 11, trimming his position by 8.27% to 44,379 shares (valued at ~$22.41M); the transaction was disclosed in an SEC filing.
- Strong quarterly results and guidance: HCA reported $8.01 EPS (beating estimates), revenue rose 6.7% YoY to $19.51B, and management set FY2026 guidance of 29.10–31.50 EPS.
- Dividend and institutional activity: the quarterly dividend was raised to $0.78 ($3.12 annualized, ~0.6% yield; ex-dividend March 17, payable March 31), and institutions now own about 62.7% of the stock after large recent purchases.
HCA Healthcare, Inc. (NYSE:HCA - Get Free Report) SVP Christopher Wyatt sold 4,000 shares of the business's stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $505.00, for a total value of $2,020,000.00. Following the sale, the senior vice president directly owned 44,379 shares of the company's stock, valued at $22,411,395. This represents a 8.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
HCA Healthcare Trading Up 0.7%
Shares of NYSE:HCA opened at $535.24 on Friday. HCA Healthcare, Inc. has a 12-month low of $295.00 and a 12-month high of $552.90. The company has a market cap of $119.69 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 1.63 and a beta of 1.36. The stock has a 50 day moving average of $481.73 and a 200 day moving average of $446.85.
HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 earnings per share for the quarter, topping analysts' consensus estimates of $7.37 by $0.64. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The business had revenue of $19.51 billion during the quarter, compared to analyst estimates of $19.67 billion. During the same period in the prior year, the business posted $6.22 earnings per share. The company's revenue was up 6.7% on a year-over-year basis. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Equities research analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.
HCA Healthcare Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 17th will be paid a $0.78 dividend. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.6%. This is a positive change from HCA Healthcare's previous quarterly dividend of $0.72. The ex-dividend date of this dividend is Tuesday, March 17th. HCA Healthcare's dividend payout ratio is currently 10.15%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in HCA. Norges Bank purchased a new stake in shares of HCA Healthcare during the 2nd quarter worth $1,152,408,000. Pacer Advisors Inc. boosted its holdings in shares of HCA Healthcare by 6,115.3% in the 3rd quarter. Pacer Advisors Inc. now owns 911,096 shares of the company's stock valued at $388,309,000 after buying an additional 896,437 shares in the last quarter. Life Cycle Investment Partners Ltd bought a new position in shares of HCA Healthcare during the 4th quarter worth approximately $374,037,000. Viking Global Investors LP boosted its stake in HCA Healthcare by 58.5% in the second quarter. Viking Global Investors LP now owns 1,872,133 shares of the company's stock valued at $717,214,000 after acquiring an additional 690,773 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of HCA Healthcare by 4,545.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 663,337 shares of the company's stock worth $309,686,000 after purchasing an additional 649,058 shares in the last quarter. 62.73% of the stock is currently owned by hedge funds and other institutional investors.
More HCA Healthcare News
Here are the key news stories impacting HCA Healthcare this week:
- Positive Sentiment: Zacks Research raised FY-2026 EPS to $29.31 (from $28.47) and lifted multiple quarterly and multi‑year estimates (FY2027 to $33.44, FY2028 to $37.67), aligning analyst expectations with HCA’s FY2026 guidance and suggesting stronger forward profitability. Zacks remains at a "Hold" rating, but the higher estimates support valuation and earnings momentum. Zacks estimate changes (MarketBeat)
- Neutral Sentiment: HCA’s StoneSprings Hospital Center is planning to convert a Chantilly deli site into a freestanding emergency room — a local expansion that could modestly increase patient volumes and admissions in that market over time. HCA StoneSprings freestanding ER
- Neutral Sentiment: HCA-related ASC real estate was sold, a move that can free capital or change lease/operating dynamics for ambulatory surgery centers; the net effect depends on deal terms and use of proceeds. HCA ASC real estate sold
- Neutral Sentiment: Executive moves: a former HCA Florida executive joined Memorial Health as COO and an HCA veteran was named COO at Memorial Health in Georgia — routine industry leadership turnover that may have limited near‑term impact on HCA’s financials but is notable for regional competitive dynamics and management talent flow. Former HCA exec joins Memorial Health (MSN) HCA veteran named COO (Becker's)
Wall Street Analysts Forecast Growth
HCA has been the topic of several recent analyst reports. Zacks Research cut shares of HCA Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Thursday, November 27th. Mizuho set a $540.00 target price on shares of HCA Healthcare in a research note on Monday, February 2nd. Leerink Partners lifted their target price on HCA Healthcare from $507.00 to $573.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 28th. Stephens lifted their price target on shares of HCA Healthcare from $450.00 to $500.00 and gave the company an "overweight" rating in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of HCA Healthcare in a report on Monday, December 29th. Sixteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $523.27.
Read Our Latest Stock Analysis on HCA Healthcare
HCA Healthcare Company Profile
(
Get Free Report)
HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.
The company's core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA's services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
